To read the full story, subscribe or sign in.

Genmab Pays $240M for PDL's Antibody Manufacturing Facility

Feb. 22, 2008

Strengthening its position as a major antibody player, Genmab A/S said it is securing its own manufacturing capability in a deal to acquire troubled PDL BioPharma Inc.'s Brooklyn, Minn., facility for $240 million. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Jan 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 5, 2026.

AND-017 increases RBC and hemoglobin in sickle cell disease

BioWorld Science

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...